Literature DB >> 20020536

Pathogenic mutations cause rapid degradation of lysosomal storage disease-related membrane protein CLN6.

Anna-Katherina Kurze1, Giovanna Galliciotti, Claudia Heine, Sara E Mole, Arne Quitsch, Thomas Braulke.   

Abstract

One variant form of late infantile neuronal ceroid lipofuscinosis is an autosomal recessive inherited neurodegenerative lysosomal storage disorder caused by mutations in the CLN6gene. The function of the polytopic CLN6 membrane protein localized in the endoplasmic reticulum is unknown. Here we report on expression studies of three mutations (c.368G>A, c.460-462delATC, c.316insC) found in CLN6 patients predicted to affect transmembrane domain 3 (p.Gly123Asp), cytoplasmic loop 2 (p.Ile154del) or result in a truncated membrane protein (p.Arg106ProfsX26), respectively. The rate of synthesis and the stability of the mutant CLN6 proteins are reduced in a mutation-dependent manner. None of the mutations prevented the dimerization of the CLN6 polypeptides. The particularly rapid degradation of the p.Arg106ProfsX26 mutant which is identical with the mutation in the murine orthologue Cln6 gene in the nclf mouse model of the disease, can be strongly inhibited by proteasomal and partially by lysosomal protease inhibitors. Both degradative pathways seem to be sufficient to prevent the accumulation/aggregation of the mutant CLN6 polypeptides in the endoplasmic reticulum.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20020536     DOI: 10.1002/humu.21184

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.

Authors:  Todor Arsov; Katherine R Smith; John Damiano; Silvana Franceschetti; Laura Canafoglia; Catherine J Bromhead; Eva Andermann; Danya F Vears; Patrick Cossette; Sulekha Rajagopalan; Alan McDougall; Vito Sofia; Michael Farrell; Umberto Aguglia; Andrea Zini; Stefano Meletti; Michela Morbin; Saul Mullen; Frederick Andermann; Sara E Mole; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

2.  Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation.

Authors:  Myriam Mirza; Cornelia Volz; Marcus Karlstetter; Monica Langiu; Aleksandra Somogyi; Mika O Ruonala; Ernst R Tamm; Herbert Jägle; Thomas Langmann
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

3.  Disruption of the autophagy-lysosome pathway is involved in neuropathology of the nclf mouse model of neuronal ceroid lipofuscinosis.

Authors:  Melanie Thelen; Markus Damme; Markus Daμμe; Michaela Schweizer; Christian Hagel; Andrew M S Wong; Jonathan D Cooper; Thomas Braulke; Giovanna Galliciotti
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

4.  A missense mutation in canine CLN6 in an Australian shepherd with neuronal ceroid lipofuscinosis.

Authors:  Martin L Katz; Fabiana H Farias; Douglas N Sanders; Rong Zeng; Shahnawaz Khan; Gary S Johnson; Dennis P O'Brien
Journal:  J Biomed Biotechnol       Date:  2010-12-22

5.  Sustained Neural Stem Cell-Based Intraocular Delivery of CNTF Attenuates Photoreceptor Loss in the nclf Mouse Model of Neuronal Ceroid Lipofuscinosis.

Authors:  Wanda Jankowiak; Katharina Kruszewski; Kai Flachsbarth; Christos Skevas; Gisbert Richard; Klaus Rüther; Thomas Braulke; Udo Bartsch
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

6.  Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease.

Authors:  Jacob T Cain; Shibi Likhite; Katherine A White; Derek J Timm; Samantha S Davis; Tyler B Johnson; Cassandra N Dennys-Rivers; Federica Rinaldi; Dario Motti; Sarah Corcoran; Pablo Morales; Christopher Pierson; Stephanie M Hughes; Stella Y Lee; Brian K Kaspar; Kathrin Meyer; Jill M Weimer
Journal:  Mol Ther       Date:  2019-07-10       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.